CADE proposes remedy for GSK/Pfizer
The investigative arm of Brazil’s competition authority has raised concerns that GlaxoSmithKline’s pending acquisition of Pfizer’s consumer healthcare division could lead to higher prices for simple antacids.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10